Clinical Trials Logo

Hemorrhagic Fever clinical trials

View clinical trials related to Hemorrhagic Fever.

Filter by:
  • None
  • Page 1

NCT ID: NCT04283513 Not yet recruiting - Hemorrhagic Fever Clinical Trials

Treatment of Hemorrhagic Fever With Ribavirin

Start date: October 31, 2022
Phase: Phase 2
Study type: Interventional

Multisite protocol to provide IV Ribavirin treatment to patients with probable or suspected case of Hemorrhagic Fever with Renal Syndrome (HFRS)

NCT ID: NCT02368119 Completed - Ebola Virus Disease Clinical Trials

Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)

Start date: March 2015
Phase: Phase 1
Study type: Interventional

Ebola virus causes an infection known as Ebola virus disease (EVD). This it is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever. Researchers want to develop a vaccine to prevent Ebola infection. This study will assess the safety of a single dose of the bivalent Ebola Zaire candidate vaccine VRC-EBOADC069-00-VP (cAD3-EBO) when administered to healthy Malian adult volunteers, age 18-65 years (mostly health care workers and other front line workers [e.g., individuals who incinerate contaminated materials]), at one of 2 dosage levels, 2.0 x 10(10) vp or 2 x 10(11) vp. It is impossible for someone to get an Ebola infection from this vaccine. Heterologous booster dose allocation - Each participant will be offered the opportunity to be included in the booster step of this study. After obtaining consent and the additional review of pertinent medical history, participants in each group will be randomized to receive the candidate booster vaccine, MVA-EbolaZ or placebo. This will be the first clinical trial in Mali with bivalent cAd3-based Ebola vaccine and the first where the dosage level contains > 10(11) vp. It follows completion of a Phase Ib trial in Malian health care workers that tested three dosage levels of monovalent cAd3-EBO Z vaccine. The data generated in West Africans (Mali) on the tolerability and immunogenicity of the bivalent vaccine will be compared to clinical and immunologic responses documented in in parallel studies in East African subjects (Uganda) and North American subjects (NIH, Bethesda, MD, USA). Objectives: - To see if an Ebola vaccine is safe and to study immune responses to it. - To study the effect of the MVA-EbolaZ booster on the immune response Eligibility: - Healthy adults ages 18-65.

NCT ID: NCT02267109 Completed - Ebola Virus Disease Clinical Trials

Phase 1 Trial of Ebola Vaccine in Mali

Start date: October 2014
Phase: Phase 1
Study type: Interventional

Ebola virus causes an infection known as Ebola virus disease (EVD). This is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever. Researchers want to develop a vaccine to prevent Ebola infection. It is impossible for someone to get an Ebola infection from this vaccine.